801 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Robinson Smith Wealth Advisors LLC

Robinson Smith Wealth Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 801 shares of the biopharmaceutical company’s stock, valued at approximately $704,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. FMR LLC lifted its position in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after buying an additional 669,517 shares in the last quarter. Northern Trust Corp lifted its position in Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after buying an additional 34,326 shares in the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $932,571,000. Morgan Stanley lifted its position in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after buying an additional 25,792 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock worth $754,422,000 after buying an additional 30,050 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,785 shares of company stock worth $53,510,873. Corporate insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $989.36.

Read Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $10.25 during midday trading on Friday, hitting $980.16. The company had a trading volume of 833,169 shares, compared to its average volume of 348,037. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The stock has a market cap of $108.00 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 2.02 and a beta of 0.17. The firm has a fifty day simple moving average of $945.79 and a two-hundred day simple moving average of $921.80. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.